PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
15.43%
R&D growth while RVPH reduces spending. John Neff would investigate strategic advantage.
12.93%
G&A growth while RVPH reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
5.37%
Other expenses change of 5.37% while RVPH maintains costs. Bruce Berkowitz would investigate efficiency.
14.34%
Operating expenses growth while RVPH reduces costs. John Neff would investigate differences.
14.34%
Total costs growth while RVPH reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
5.37%
D&A change of 5.37% while RVPH maintains D&A. Bruce Berkowitz would investigate efficiency.
-16.61%
EBITDA decline while RVPH shows 5.85% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-14.34%
Operating income decline while RVPH shows 7.11% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-295.23%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-20.40%
Pre-tax income decline while RVPH shows 5.94% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-20.40%
Net income decline while RVPH shows 5.90% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-19.61%
EPS decline while RVPH shows 7.69% growth. Joel Greenblatt would examine position.
-20.61%
Diluted EPS decline while RVPH shows 7.69% growth. Joel Greenblatt would examine position.
0.76%
Share count reduction exceeding 1.5x RVPH's 2.47%. David Dodd would verify capital allocation.
No Data
No Data available this quarter, please select a different quarter.